News from Novartis Pharmaceuticals Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

06 Mar, 2017, 01:30 ET Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

Novartis announced today a new analysis (post hoc) of an uncontrolled extension study which shows moderate to severe plaque psoriasis patients...


09 Dec, 2016, 08:30 ET Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

Novartis announced today additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly...


16 Nov, 2016, 07:30 ET Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer

Novartis will present data demonstrating the latest advancements from its oncology research program at the 58th American Society of Hematology...


10 Nov, 2016, 08:00 ET Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones

Novartis Pharmaceuticals Corporation announced today the launch of Together in HF (www.TogetherinHF.com) – a social network for members of the...


01 Nov, 2016, 07:30 ET Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

Novartis announced today that the US Food and Drug Administration (FDA) accepted the company's New Drug Application (NDA) for filing and granted...


08 Oct, 2016, 08:00 ET Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS)...


01 Oct, 2016, 01:33 ET Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years

 Novartis announced today new data showing Cosentyx® (secukinumab) delivers efficacy in patients with moderate to severe plaque psoriasis...


23 Sep, 2016, 13:11 ET Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions

Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of...


19 Sep, 2016, 01:22 ET Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients

 A new post-hoc analysis demonstrates that the decline in health-related quality of life (HRQL) scores associated with a heart failure (HF)...


14 Sep, 2016, 07:30 ET Novartis survey published in The Breast Journal reveals major gaps in treatment discussions between metastatic breast cancer patients and doctors

Novartis announced today the publication of the Make Your Dialogue Count survey results in The Breast Journal, a first-of-its-kind survey designed...


03 Aug, 2016, 07:00 ET Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

 Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib),...


07 Jul, 2016, 16:40 ET Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma

Novartis today announced that the US Food and Drug Administration (FDA) has approved an expanded age range for Xolair® (omalizumab) to include...


29 Jun, 2016, 17:15 ET Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)

 Novartis announced today that The New England Journal of Medicine (NEJM) published data for PKC412 (midostaurin) demonstrating an overall...


22 Jun, 2016, 11:35 ET Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

 A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto® (sacubitril/valsartan) by all...


06 Jun, 2016, 14:40 ET Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

 Novartis today announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive...


04 Jun, 2016, 16:05 ET Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

 Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna...


03 Jun, 2016, 08:00 ET Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS

 Novartis today announced data from a randomized, prospective, Phase IV, open-label study that demonstrated patient retention rate with...


02 Jun, 2016, 16:17 ET Novartis announces US collaboration to co-promote Lenvima® in combination with everolimus for advanced renal cell carcinoma (RCC)

Novartis Pharmaceuticals Corporation today announced an agreement with Eisai Inc. to collaborate on commercial and certain medical affairs...


18 May, 2016, 17:09 ET Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

Novartis will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical...


26 Feb, 2016, 15:43 ET FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)

Novartis today announced that the United States Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment...


19 Feb, 2016, 07:15 ET Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)

 Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PKC412...


26 Jan, 2016, 09:47 ET Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for two new indications -...


25 Jan, 2016, 16:30 ET Novartis teams up with Pro Football Hall of Famer Troy Aikman on advanced melanoma educational and community support program

 Pro Football Legend, Hall of Famer and former melanoma patient Troy Aikman is teaming up with Novartis and the advocacy community to educate...


23 Dec, 2015, 17:04 ET Novartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis

 Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing...


07 Dec, 2015, 15:03 ET Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL

The latest findings from an ongoing Phase II study of CTL019, an investigational chimeric antigen receptor T cell (CART) therapy, further support...